Background To estimate the prognostic relevance of human papillomavirus (HPV) 16 and HPV 18 in patients with cervical cancer. Method We searched PubMed, EMBASE, American Society of Clinical Oncology (ASCO) and the European Society of Medical Oncology (ESMO), CNKI, and Wanfang databases to search primary articles illustrating the survival outcomes in cervical cancer patients with or without HPV 16/18 infection. A meta-analysis was conducted to generate a combined hazard ratio (HR) with 95% confidence intervals (CI) for progression-free survival (PFS), disease free survival (DFS) and overall survival (OS). Results A total of 13 studies were included. Our meta-analysis revealed that HPV 16 positive did not have any impact on OS (HR, 0.76; 95% CI = 0.37–1.54; P = 0.44). Cervical cancer patiensts infected with HPV 18 had worse OS (HR, 1.66; 95% CI = 1.28–2.17; P = 0.0001), DFS (HR, 2.10; 95% CI = 1.73–2.54; P < 0.0001) and worse PFS (HR, 2.97; 95% CI = 1.69–5.23; P = 0.00012) compared with those not infected with HPV 18. cervical cancer patiensts infected with HPV 18 had worse PFS compared with those infected with HPV 16 ((HR, 1.34; 95% CI = 1.06–1.70; P = 0.01). Conclusion Cervical cancer patients infected with HPV 18 had worse survival compared with cervical cancer patients with HPV 16 infection.

中文翻译：

---

宫颈癌患者中人乳头瘤病毒类型的预后意义：系统评价和荟萃分析

背景 评估人乳头瘤病毒 (HPV) 16 和 HPV 18 在宫颈癌患者中的预后相关性。方法 我们检索了 PubMed、EMBASE、美国临床肿瘤学会 (ASCO) 和欧洲肿瘤内科学会 (ESMO)、CNKI 和万方数据库，以搜索说明有或没有 HPV 16/18 的宫颈癌患者生存结果的主要文章感染。进行荟萃分析以生成无进展生存期 (PFS)、无病生存期 (DFS) 和总生存期 (OS) 的组合风险比 (HR) 和 95% 置信区间 (CI)。结果共纳入13项研究。我们的荟萃分析显示，HPV 16 阳性对 OS 没有任何影响（HR，0.76；95% CI = 0.37–1.54；P = 0.44）。感染 HPV 18 的宫颈癌患者的 OS 较差（HR，1.66；95% CI = 1。28–2.17；P = 0.0001）、DFS（HR，2.10；95% CI = 1.73–2.54；P < 0.0001）和更差的 PFS（HR，2.97；95% CI = 1.69–5.23；P = 0.00012）与未感染 HPV 的患者相比18. HPV 18 感染的宫颈癌患者与 HPV 16 感染的患者相比，PFS 更差（（HR，1.34；95% CI = 1.06-1.70；P = 0.01）。结论 HPV 18 感染的宫颈癌患者生存率更差患有 HPV 16 感染的宫颈癌患者。